COVID-19 treatment, Keytruda boost Merck in 1Q
Better-than-expected sales of its COVID-19 treatment and the cancer blockbuster Keytruda helped push Merck past profit forecasts in the first quarter
Better-than-expected sales of its COVID-19 treatment and the cancer blockbuster Keytruda helped push Merck past profit forecasts in the first quarter